The human results are mixed, with small open-label studies encouraging but the controlled phase 2 OVERTURE trial missing its primary endpoint, and the larger pivotal trial has finished enrolling with results pending, so for now it is best read as mechanistically promising and clinically unproven
Six participants cannot define a treatment effect A crossover design can be useful for exploratory research, but a study involving six people cannot establish uncommon risks, long-term effectiveness or suitability for people with different health conditions
Moving release farther down the intestinal tract changes the pH, enzymes, transit conditions, mucus layer, surface area, and local concentration around the formulation
Evidence of toxicity, oxidative stress, and neuronal insult in autism